The deal puts the entire valuation of Syngene International Ltd, a wholly-owned subsidiary of Biocon Ltd, at Rs 3,800 crore.
"This investment reflects Syngene's leading position in the contract research and manufacturing space in Asia, acknowledging its comprehensive multidisciplinary capabilities," Biocon Chairman and Managing Director Kiran Mazumdar-Shaw said in a statement.
This transaction is part of the overall strategic plan for Syngene and sets a new benchmark as we prepare the company for listing, she added.
Post the completion of the transaction, Biocon and BRL will jointly hold 85.54 per cent stake in Syngene, it added.
Commenting on the development, IVFA Managing Director Vishal Nevatia said: "We had partnered with Biocon through our first fund in 2003. We are excited to partner with them again...This deal showcases the IVFA investment philosophy of working with high quality entrepreneurs and management teams."
Biocon shares today closed at Rs 499.95 apiece on the BSE, up 2.70 per cent from its previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
